Transcription Factor Systems for Tunable Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene and cell therapy technologies lack tunability in protein expression timing and levels, making it difficult to safely and effectively deploy therapies for proteins with narrow therapeutic windows or transient expression requirements.
Innovation Solution
Development of modified cells and nucleic acid molecules incorporating transcription factor systems with drug-responsive domains (DRDs) that allow for regulated protein expression through oral small molecule administration, enabling tunable regulation of protein expression by linking transcription factors to DRDs and inducible promoters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current gene and cell therapy technologies are used, then protein expression can be achieved, but tunability in timing and levels of protein expression is lacking
Solution Approach 1:
The system is divided into separate modular components: a transcription factor with drug-responsive domain, an inducible promoter with specific binding sites, and a payload gene. This segmentation allows independent optimization and tuning of each component while maintaining overall system functionality, directly addressing the need for tunable protein expression.
Solution Approach 2:
A drug-responsive domain acts as an intermediary between the administered small molecule drug and the transcription factor. This intermediary mechanism enables external control of gene expression through drug administration, providing the desired tunability in timing and levels of protein expression without directly modifying the core genetic elements.
2Reliability
If protein expression is increased for therapeutic effect, then therapeutic benefit is improved, but safety control for proteins with narrow therapeutic windows becomes difficult
Solution Approach 1:
The system incorporates feedback control through drug administration. The level of protein expression can be adjusted by varying the dose and timing of the administered small molecule drug, allowing real-time modulation of expression levels to maintain them within the narrow therapeutic window while ensuring safety.
Solution Approach 2:
The system transitions from static to dynamic control of protein expression. By using inducible promoters responsive to administered drugs, the expression levels can be dynamically adjusted according to therapeutic needs, enabling precise control over when and how much protein is produced to match the narrow therapeutic window requirements.
3Reliability
If transient protein expression is required, then therapeutic specificity is improved, but maintaining controlled expression timing becomes challenging
Solution Approach 1:
The system is pre-configured with inducible promoters and drug-responsive elements before protein expression is needed. The genetic circuit is established in advance, ready to be activated by simple drug administration, thereby achieving precise temporal control of expression without complex operational procedures at the time of expression induction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise and controlled expression of therapeutic proteins, enhancing the safety and efficacy of gene and cell therapies by allowing for temporal and quantitative control of protein production.
Implementation Method 1
the DRD is configured to bind to a small molecule ligand... when the small molecule ligand binds to the DRD, the transcription factor is stabilized
Data Source
AI summary
The present disclosure provides compositions and methods related to transcription factor systems. Such systems provide for modular and tunable protein expression driven by regulated transcriptional activity.